Recent developments of point-of-care (POC) testing platform for biomolecules

Manmana, Yanawut; Kubo, Takuya; Otsuka, Koji

doi:10.1016/j.trac.2020.116160

Cited by 59 publications

(27 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many well-established conventional non-microfluidic integrated diagnostic techniques can struggle to address the first ASSURED criteria of affordability due to their diagnostic techniques often requiring costly reagents, fabrication material, knowledgeable operators and laboratory-grade equipment [ 40 , 41 ]. Microfluidic integration could greatly improve affordability by reducing global costs related to reagent volumes and fabrication materials through the size reduction of diagnostic systems from the lab scale to the microscale.…”

Section: Integrated Microfluidic-based Platforms (Imps)mentioning

confidence: 99%

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Escobar

Chiu

et al. 2021

Micromachines

View full text Add to dashboard Cite

The rapid detection and quantification of infectious pathogens is an essential component to the control of potentially lethal outbreaks among human populations worldwide. Several of these highly infectious pathogens, such as Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been cemented in human history as causing epidemics or pandemics due to their lethality and contagiousness. SARS-CoV-2 is an example of these highly infectious pathogens that have recently become one of the leading causes of globally reported deaths, creating one of the worst economic downturns and health crises in the last century. As a result, the necessity for highly accurate and increasingly rapid on-site diagnostic platforms for highly infectious pathogens, such as SARS-CoV-2, has grown dramatically over the last two years. Current conventional non-microfluidic diagnostic techniques have limitations in their effectiveness as on-site devices due to their large turnaround times, operational costs and the need for laboratory equipment. In this review, we first present criteria, both novel and previously determined, as a foundation for the development of effective and viable on-site microfluidic diagnostic platforms for several notable pathogens, including SARS-CoV-2. This list of criteria includes standards that were set out by the WHO, as well as our own “seven pillars” for effective microfluidic integration. We then evaluate the use of microfluidic integration to improve upon currently, and previously, existing platforms for the detection of infectious pathogens. Finally, we discuss a stage-wise means to translate our findings into a fundamental framework towards the development of more effective on-site SARS-CoV-2 microfluidic-integrated platforms that may facilitate future pandemic diagnostic and research endeavors. Through microfluidic integration, many limitations in currently existing infectious pathogen diagnostic platforms can be eliminated or improved upon.

show abstract

Section: Integrated Microfluidic-based Platforms (Imps)mentioning

confidence: 99%

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Escobar

Chiu

et al. 2021

Micromachines

View full text Add to dashboard Cite

show abstract

“…To bridge the gap between POC testing with LFA and remote (clinical lab) testing with ELISA or CLIA, several alternative POC testing formats are being developed such as lab-on-a-chip (LOC) and lab-on-a-disc (LOAD) [ 4 , 13 , 14 , 15 ]. Integration of microfluidics in the POC device might be beneficial as it offers possibilities for improving compactness and limiting reagent consumption and might also help in further reducing the amount of required patient sample [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma

et al. 2022

View full text Add to dashboard Cite

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic has once more emphasized the urgent need for accurate and fast point-of-care (POC) diagnostics for outbreak control and prevention. The main challenge in the development of POC in vitro diagnostics (IVD) is to combine a short time to result with a high sensitivity, and to keep the testing cost-effective. In this respect, sensors based on photonic integrated circuits (PICs) may offer advantages as they have features such as a high analytical sensitivity, capability for multiplexing, ease of miniaturization, and the potential for high-volume manufacturing. One special type of PIC sensor is the asymmetric Mach–Zehnder Interferometer (aMZI), which is characterized by a high and tunable analytical sensitivity. The current work describes the application of an aMZI-based biosensor platform for sensitive and multiplex detection of anti-SARS-CoV-2 antibodies in human plasma samples using the spike protein (SP), the receptor-binding domain (RBD), and the nucleocapsid protein (NP) as target antigens. The results are in good agreement with several CE-IVD marked reference methods and demonstrate the potential of the aMZI biosensor technology for further development into a photonic IVD platform.

show abstract

“…each approach has its pros and cons. Point-of-care (POC) diagnostic devices are of paramount importance for both resource rich and constrained settings [2]. Introducing a biosensing approach that meets the ASSURED (affordable, sensitive, specific, userfriendly, rapid and robust, equipment-free and deliverable to end users) criteria defined by the world health organization (WHO) [3] always remains a prime focus of a biosensing study.…”

Section: Introductionmentioning

confidence: 99%

Angiotensin-converting enzyme 2-based biosensing modalities and devices for coronavirus detection

Gul¹,

Zhai²,

Zhong³

et al. 2022

Preprint

View full text Add to dashboard Cite

Rapid and cost-effective diagnostic tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have become a critical and valuable weapon for the coronavirus disease 2019 (COVID-19) pandemic response. SARS-CoV-2 invasion is primarily mediated by human angiotensin-converting enzyme 2 (hACE2). Recent developments in ACE2-based SARS-CoV-2 detection modalities accentuate the potential of this natural host-virus interaction for developing point-of-care (POC) COVID-19 diagnostic tools and devices. Although research on harnessing ACE2 for SARS-CoV-2 detection is in its infancy, some interesting biosensing devices have been developed, showing the commercial viability of this intriguing new approach. The exquisite performance of the reported ACE2-based COVID-19 biosensors provides opportunities for researchers to develop rapid detection tools suitable for testing at points of entry, workplaces, or congregate scenarios in order to effectively implement pandemic control and management plans. However, to be considered as an emerging approach, the rationale for ACE2-based biosensing needs to be critically and comprehensively surveyed and discussed. Herein, we review the current status of ACE2-based detection methods, the signal transduction principles in ACE2 biosensors and the development trend in the future. We discuss the challenges to development of ACE2-biosensors and delineate prospects for their use, along with recommended solutions and suggestions

show abstract

Recent developments of point-of-care (POC) testing platform for biomolecules

Cited by 59 publications

References 116 publications

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Integrated Microfluidic-Based Platforms for On-Site Detection and Quantification of Infectious Pathogens: Towards On-Site Medical Translation of SARS-CoV-2 Diagnostic Platforms

Asymmetric Mach–Zehnder Interferometric Biosensing for Quantitative and Sensitive Multiplex Detection of Anti-SARS-CoV-2 Antibodies in Human Plasma

Angiotensin-converting enzyme 2-based biosensing modalities and devices for coronavirus detection

Contact Info

Product

Resources

About